Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Severe Losses
AIAI Summary
ALMS is now a high-risk, psoriasis-led regulatory investment: the Q4 2026 envudeucitinib NDA is the pivotal value catalyst, while the failed broad SLE study reduces lupus to a speculative biomarker option. Investors should await evidence of filing/approval progress and protect against downside from heavy cash burn, potential dilution, and failure to reclaim clinical or commercial differentiation in a crowded psoriasis market.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Severe Losses
ALMS has ample liquidity and low debt, but extreme losses, rapid cash burn, and a premium valuation make the shares high risk pending clear operational improvement.
Price Behavior
Key Price Behavior Insights:
- •Sharp Downtrend
- •Key Support
- •Failed Rebounds
ALMS remains technically weak after a ~66% last-month decline, with $7.77 support critical and recovery requiring a break above $9.22.
Sharp late-August/early-September drop suggests a possible corporate-action adjustment
Sentiment & News
Key News Insights:
- •Lupus trial miss
- •Subgroup signal
- •Psoriasis on track
Alumis' lupus trial failure is a major setback, but promising subgroup data and its on-track psoriasis filing preserve upside potential.
Near-term sentiment is negative, though psoriasis progress may provide an important valuation catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings